Disease · HP_0000938
Osteopenia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Osteopenia. Diseases, record HP_0000938. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000938
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ALENDRONIC ACID | CHEMBL870 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 5 | Drugs and targets |
| RISEDRONIC ACID | CHEMBL923 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ZOLEDRONIC ACID | CHEMBL4303669 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| DENOSUMAB | CHEMBL1237023 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| IBANDRONIC ACID | CHEMBL997 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ZOLEDRONIC ACID ANHYDROUS | CHEMBL924 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| LEVONORGESTREL | CHEMBL1389 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PRASTERONE | CHEMBL90593 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOXYCYCLINE HYCLATE | CHEMBL3989740 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROGLYCERIN | CHEMBL730 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets21
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FDPS | Farnesyl pyrophosphate synthase | 6 | Farnesyl diphosphate synthase inhibitor | Phase 3 | https://conductscience.org/library/genes/2224 | Drugs and targets |
| CTSK | Cathepsin K | 2 | Cathepsin K inhibitor | Phase 2 | https://conductscience.org/library/genes/1513 | Drugs and targets |
| ADRB1 | Beta-1 adrenergic receptor | 1 | Beta-1 adrenergic receptor antagonist | Unknown | https://conductscience.org/library/genes/153 | Drugs and targets |
| AR | Androgen receptor | 1 | Androgen Receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/367 | Drugs and targets |
| CALCR | Calcitonin receptor | 1 | Calcitonin receptor agonist | Unknown | https://conductscience.org/library/genes/799 | Drugs and targets |
| CYP19A1 | Aromatase | 1 | Cytochrome P450 19A1 inhibitor | Unknown | https://conductscience.org/library/genes/1588 | Drugs and targets |
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha agonist | Phase 2 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| GUCY1A1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2982 | Drugs and targets |
| GUCY1A2 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2977 | Drugs and targets |
| GUCY1B1 | Soluble guanylate cyclase | 1 | Soluble guanylate cyclase activator | Phase 3 | https://conductscience.org/library/genes/2983 | Drugs and targets |
1 to 10 of 21
See all 21 targetsTrials38
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00404820 | Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis | Phase 3 | 604 | 2011-07-01 | Osteoporosis | ALENDRONIC ACID, ZOLEDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT02355821 | Comparative Effects of Moxonidine on Bone Metabolism, Vascular and Cellular Aging in Hypertensive Postmenopausal Women | Not applicable | 114 | 2021-09-01 | Osteopenia, Arterial Hypertension | BISOPROLOL, MOXONIDINE | Its record names the disease | ClinicalTrials.gov |
| NCT01690000 | Treatment of Osteopenia With Melatonin | Not applicable | 81 | 2016-05-06 | Osteoporosis | MELATONIN | Its record names the disease | ClinicalTrials.gov |
| NCT00310791 | Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa | Phase 2/3 | 80 | 2013-02-01 | Anorexia Nervosa | ESTROGEN, PRASTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT00089843 | Bone Loss in Women With Anorexia Nervosa | Phase 2/3 | 77 | 2012-06-01 | Anorexia Nervosa | RISEDRONIC ACID, TESTOSTERONE | Its record names the disease | ClinicalTrials.gov |
| NCT00436917 | Zoledronate in Treating Osteopenia or Osteoporosis in Postmenopausal Women Receiving Letrozole for Stage I, Stage II, or Stage IIIA Primary Breast Cancer | Not applicable | 60 | 2011-08-12 | Breast Cancer, Osteoporosis | LETROZOLE, ZOLEDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00720122 | Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa | Phase 2 | 28 | 2012-02-29 | Disorder of Bone Density and Structure, Unspecified | MECASERMIN | Its record names the disease | ClinicalTrials.gov |
| NCT02475265 | Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa | Phase 2 | 11 | 2019-07-22 | Anorexia Nervosa, Osteoporosis | ESTRADIOL, LEVONORGESTREL | Its record names the disease | ClinicalTrials.gov |
| NCT00145704 | Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density | Not applicable | 6 | 2013-04-08 | Osteopenia | RISEDRONIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT00355953 | Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women | Phase 2/3 | 400 | Menopause, Osteopenia | GENISTEIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials9
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Zoledronic Acid 5 mg vs Alendronate 70 mg: serious adverse events | 43 of 408 | 21 of 194 | 602 | NCT00404820 | Trial comparisons |
| Zoledronic Acid 5 mg vs Alendronate 70 mg: Number of Patients With a Clinical Fracture From Baseline to Month 12 | 10 of 408 | 4 of 191 | 599 | NCT00404820 | Trial comparisons |
| Moxonidine vs Bisoprolol: THe Number (Percentage) of the Treatment Responders | 55 of 57 | 53 of 57 | 114 | NCT02355821 | Trial comparisons |
| Moxonidine vs Bisoprolol: Number of Participants With Adverse Events (AE) | 3 of 57 | 3 of 57 | 114 | NCT02355821 | Trial comparisons |
| Moxonidine vs Bisoprolol: deaths from any cause | 0 of 57 | 0 of 57 | 114 | NCT02355821 | Trial comparisons |
| Moxonidine vs Bisoprolol: serious adverse events | 0 of 57 | 0 of 57 | 114 | NCT02355821 | Trial comparisons |
| Melatonin1+3 vs Placebo: serious adverse events | 5 of 40 | 7 of 41 | 81 | NCT01690000 | Trial comparisons |
| Active vs Placebo: serious adverse events | 0 of 40 | 0 of 40 | 80 | NCT00310791 | Trial comparisons |
| Bisphosphonate and Growth Hormone Use vs Growth Hormone Only: serious adverse events | 0 of 3 | 0 of 3 | 6 | NCT00145704 | Trial comparisons |
Papers from its trials34
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000938
GET https://conductscience.org/api/diseases/v1/HP_0000938/drugs?page=2